Circuit Court Sides With PTAB on Invalidating J&J’s Remicade Patent

Drug Industry Daily
A A
A federal circuit court upheld a PTO Patent Trial and Appeal Board ruling that a Johnson & Johnson patent for Remicade, which earned the company nearly $7 billion in 2016, is invalid.

To View This Article:

Login

Subscribe To Drug Industry Daily